Evidence map›Paper›PMID 30912762›Full record

ArticleJMIR mental health2019

Caregiver Daily Reporting of Symptoms in Autism Spectrum Disorder: Observational Study Using Web and Mobile Apps.

Abigail Bangerter, Nikolay V Manyakov, David Lewin, Matthew Boice, Andrew Skalkin, Shyla Jagannatha, Meenakshi Chatterjee, Geraldine Dawson, Matthew S Goodwin, Robert Hendren and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JMIR mental health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02668991 (A Study to Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder and in a Normally Developing Cohort), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02668991 completednot on this map

A Study to Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder and in a Normally Developing Cohort

TypeobservationalSponsorJanssen Research & Development, LLCRan2015 to 2016Enrolled186ConditionsAutism Spectrum Disorder
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Abigail BangerterNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0002-9360-3411
Nikolay V ManyakovComputational Biology, Discovery Sciences, Janssen Research & Development, Beerse, Belgium.ORCID http://orcid.org/0000-0001-9037-1400
David LewinClinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0002-7272-8565
Matthew BoiceNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0002-3045-8704
Andrew SkalkinInformatics, Janssen Research & Development, LLC, Spring House, PA, United States.ORCID http://orcid.org/0000-0002-9857-5202
Shyla JagannathaStatistical Decision Sciences, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0002-2632-7250
Meenakshi ChatterjeeComputational Biology, Discovery Sciences, Janssen Research & Development, LLC, Spring House, PA, United States.ORCID http://orcid.org/0000-0003-4548-8962
Geraldine DawsonDuke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, United States.ORCID http://orcid.org/0000-0003-1410-2764
Matthew S GoodwinDepartment of Health Sciences, Northeastern University, Boston, MA, United States.ORCID http://orcid.org/0000-0002-4237-601X
Robert HendrenDepartment of Psychiatry, School of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0001-8470-4862
Bennett LeventhalDepartment of Psychiatry, School of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0001-6985-3691
Frederick ShicCenter for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, United States.ORCID http://orcid.org/0000-0002-9040-1259
Seth NessNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0002-1572-7021
Gahan PandinaNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, NJ, United States.ORCID http://orcid.org/0000-0003-0050-3575
Janssen (United States) · USUniversity of California, San Francisco · USDecision Sciences (United States) · USDuke University · USJanssen (Belgium) · BENortheastern University · USSeattle Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, no medications are approved to treat core symptoms of autism spectrum disorder (ASD). One barrier to ASD medication development is the lack of validated outcome measures able to detect symptom change. Current ASD interventions are often evaluated using retrospective caregiver reports that describe general clinical presentation but often require recall of specific behaviors weeks after they occur, potentially reducing accuracy of the ratings. My JAKE, a mobile and Web-based mobile health (mHealth) app that is part of the Janssen Autism Knowledge Engine-a dynamically updated clinical research system-was designed to help caregivers of individuals with ASD to continuously log symptoms, record treatments, and track progress, to mitigate difficulties associated with retrospective reporting.

objectiveMy JAKE was deployed in an exploratory, noninterventional clinical trial to evaluate its utility and acceptability to monitor clinical outcomes in ASD. Hypotheses regarding relationships among daily tracking of symptoms, behavior, and retrospective caregiver reports were tested.

methodsCaregivers of individuals with ASD aged 6 years to adults (N=144) used the My JAKE app to make daily reports on their child's sleep quality, affect, and other self-selected specific behaviors across the 8- to 10-week observational study. The results were compared with commonly used paper-and-pencil scales acquired over a concurrent period at regular 4-week intervals.

resultsCaregiver reporting of behaviors in real time was successfully captured by My JAKE. On average, caregivers made reports 2-3 days per week across the study period. Caregivers were positive about their use of the system, with over 50% indicating that they would like to use My JAKE to track behavior outside of a clinical trial. More positive average daily reporting of overall type of day was correlated with 4 weekly reports of lower caregiver burden made at 4-week intervals (r=-0.27, P=.006, n=88) and with ASD symptoms (r=-0.42, P<.001, n=112).

conclusionsMy JAKE reporting aligned with retrospective Web-based or paper-and-pencil scales. Use of mHealth apps, such as My JAKE, has the potential to increase the validity and accuracy of caregiver-reported outcomes and could be a useful way of identifying early changes in response to intervention. Such systems may also assist caregivers in tracking symptoms and behavior outside of a clinical trial, help with personalized goal setting, and monitoring of progress, which could collectively improve understanding of and quality of life for individuals with ASD and their families.

trial registrationClinicalTrials.gov NCT02668991; https://clinicaltrials.gov/ct2/show/NCT02668991.

Indexed as

affectautism spectrum disorderecological momentary assessmentmHealthmobile apppatient reported outcome measuressymptom assessment

Identifiers

PMID30912762
PMCPMC6454343
OpenAlexW2922991047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.